terlipressin + noradrenalin + albumin

This is a combination therapy consisting of terlipressin, noradrenalin (norepinephrine), and albumin. It is used primarily in the management of hepatorenal syndrome (HRS), particularly HRS-AKI (acute kidney injury) in patients with advanced liver disease. Terlipressin is a synthetic vasopressin analogue that acts as a vasoconstrictor, reducing splanchnic blood flow and improving renal perfusion. Noradrenalin is an adrenergic agonist that increases vascular tone via alpha-adrenergic receptor stimulation, also leading to systemic vasoconstriction. Albumin serves as a plasma expander and helps maintain intravascular oncotic pressure, supporting circulatory function and enhancing the efficacy of vasoconstrictors. Combination regimens involving these agents are supported by clinical guidelines for HRS-AKI; terlipressin plus albumin is considered first-line therapy where available, while noradrenalin plus albumin may be used as an alternative or adjunctive regimen[2][3][4]. Some studies have explored the use of all three agents together for refractory cases or specific patient populations[4]. The combination aims to maximize hemodynamic support and renal recovery but carries risks such as increased incidence of adverse events including respiratory failure when terlipressin and albumin are co-administered[2][3][4].